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Abstract
Background: Lissencephaly is a severe brain malformation in part caused by mutations in the LIS1
gene. LIS1 interacts with microtubule-associated proteins, and enhances transport of microtubule
fragments. Previously we showed that LIS1 interacts with HIV-1 Tat protein and that this
interaction was mediated by WD40 domains of LIS1. In the present study, we analyze the effect of
LIS1 on Tat-mediated transcription of HIV-1 LTR.
Results: Tat-mediated HIV-1 transcription was upregulated in 293 cells transfected with LIS1
expression vector. The WD5 but not the N-terminal domain of LIS1 increases Tat-dependent HIV-
1 transcription. The effect of LIS1 was similar to the effect of okadaic acid, an inhibitor of protein
phosphatase 2A (PP2A). We then analyzed the effect of LIS1 on the activity of PP2A in vitro. We
show that LIS1 and its isolated WD5 domain but not the N-terminal domain of LIS1 blocks PP2A
activity.
Conclusion: Our results show that inhibition of PP2A by LIS1 induces HIV-1 transcription. Our
results also point to a possibility that LIS1 might function in the cells as a yet unrecognized
regulatory subunit of PP2A.
Background
Tat protein is a transcriptional activator encoded in the
genome of HIV-1 (reviewed in [1]). Tat binds to a transac-
tivation response (TAR) RNA [1] and activates HIV-1 tran-
scription by recruiting transcriptional co-activators that
include Positive Transcription Elongation Factor b and
histone acetyl transferases [2-4]. In addition to its func-
tion in HIV-1 transcription, Tat also interacts with a
number of cellular factors thus affecting host cellular
functions [5,6]. In T cells, Tat causes apoptosis by binding
to microtubules and affecting microtubule formation [7].
Tat also causes apoptosis in neurons apparently by chang-
ing polarity of the neuronal membranes [8,9]. Previously,
we reported that Tat binds to LIS1 [10]. LIS1 is a microtu-
bule binding protein and its mutation causes Lissenceph-
aly, a severe brain malformation [11]. Lissencephaly is
caused by abnormal neuronal migration during brain
development [12]. LIS1 is 45 kD protein that contains
seven WD repeats and an N terminal domain devoid of
the repeats. The WD repeats-containing proteins fold into
a beta propeller structure that participates in protein-pro-
tein interaction in cells [13]. The diverse family of WD40
proteins includes B-subunits of protein phosphatase 2A
(PP2A). PP2A is a major serine/threonine phosphatase
found mainly in the nucleus but also present in the cyto-
plasm [14]. PP2A catalytic subunit associates with the A
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subunit to form the core enzyme, and with the A and B
subunits to form the holoenzyme [15]. The B subunits are
diversified and represented by a variety of proteins rang-
ing from 45 kD to 55 kD [15-17]. B subunits target PP2A
to different locations within the cell [18-20]. PP2A was
reported to affect HIV-1 transcription both positively and
negatively. Deregulation of cellular enzymatic activity of
PP2A inhibited Tat-induced HIV-1 transcription [21,22].
Expression of the catalytic subunit of PP2A enhanced acti-
vation of HIV-1 promoter by phorbol myristate acetate
(PMA), whereas inhibition of PP2A by okadaic acid and
by fostriecin prevented activation of HIV-1 promoter [22].
In contrast, inhibition of PP2A was shown to induce
phosphorylation of Sp1 and upregulate HIV-1 transcrip-
tion [23].
In this report, we investigate the effect of LIS1, full length
or its isolated domains, on Tat mediated HIV-1 transcrip-
tion in 293 cells. We compared the effect of LIS1 with the
effect of okadaic acid, a known inhibitor of PP2A. We also
analyzed the effect of LIS1 on strong viral cytomegalovirus
(CMV) promoter and a strong cellular phosphoglycerate
kinase (PGK) promoter. Observing similar effects of LIS1
and okadaic acid, we also analyzed the effect of LIS1 on
the activity of PP2A in vitro. Our results presented here
point to LIS1 as a yet unrecognized regulator of PP2A that
may contribute to the regulation of HIV-1 transcription.
Results
LIS1 induces HIV-1 transcription
We analyzed the effect of LIS1 overexpression on HIV-1
transcription in 293 cells. Protein level of LIS1 was ele-
vated in the cells transfected with LIS1-expressing vector
as compared to the control cells transfected with the
empty vector (Fig. 1, panel A lanes 1 and 2). Immunoblot-
ting of tubulin was used as a control for equal protein load
(Fig. 1, panel A). We also expressed a Flag-tagged Bγ-sub-
unit of PP2A (Bγ) [24] and its expression was verified by
immunoblotting with anti-Flag antibodies (Fig. 1, panel
B, lane 2). Co-transfection of LIS1 expression vector with
HIV-1 LTR-Lac Z and Tat-expression vectors increased Tat-
induced transcription in 293 cells (Fig. 1, panel C, com-
pare lanes 3–5 to lane 2). In contrast, co-transfection with
the Bγ subunit of PP2A, which also contains WD40
repeats, did not increase Tat mediated HIV-1 transcription
(Fig. 1, panel C, lanes 6 to 8). Although expression of the
Bγ did not have an effect on Tat-induced transcription, we
argue that LIS1, a WD40 protein having a structural and
amino acid sequence similarity to the PP2A regulatory B-
subunit, might still function as a modulator of cellular
PP2A. Thus we compared the effect of LIS1 on HIV-1 tran-
scription with the effect of okadaic acid. Okadaic acid spe-
cifically inhibits PP2A at low concentration (0.1 – 1 nM)
and inhibits both PP1 and PP2A at higher concentration
(0.1–1  μM) [25]. Okadaic acid treatment of 293 cells
transfected with HIV-1 LTR-Lac Z and Tat expression vec-
tors showed increase in Tat-induced transcription (Fig. 2,
panel A). In contrast, okadaic acid had no effect on the
expression of the TAR RNA-deleted HIV-1 LTR-LacZ (Fig.
2, panel B). Thus taken together, these results show that in
293 cells both LIS1 and okadaic acid upregulate HIV-1
transcription.
WD5 domain of LIS1 upregulates Tat mediated 
transcription
Next we analyzed whether a particular region of LIS1 was
responsible for the increase of HIV-1 transcription. Our
previous study indicated that Tat interacts with WD5
domain of LIS1 but not with the N-terminal portion of
LIS1, which is devoid of the WD40 domains [10]. WD5
and the N terminal domain of LIS1 were expressed in bac-
teria as fusions with homeodomain-derived cell penetrat-
ing peptide to allow uptake of the fused LIS1 domains
into the mammalian cells. The expression of WD5 and N-
terminal domain of LIS1 was verified by SDS PAGE (Fig.
3A). 293 cells were transfected with HIV-1 LTR-lacZ and
Tat-expression vectors and the transfected cells were
treated with the cell permeable peptides for 24 hrs follow-
ing the transfection. Treatment of the transfected cells
with WD5 peptide increased Tat-induced transcription
(Fig. 3B). In contrast, treatment with the peptide contain-
ing N-terminal domain of LIS1 showed no effect on Tat-
transactivation (Fig. 3B). The peptides did not have a pro-
found effect on the basal HIV-1 transcription from LTR
containing a TAR deletion (Fig. 3C). Taken together, these
results suggest that WD5 domain of LIS1 might be respon-
sible for the induction of HIV-1 transcription. To deter-
mine whether the effect of LIS1 on the HIV-1 promoter
was specific, we transfected 293T cells with vectors
expressing EGFP under the control of viral cytomegalovi-
rus (CMV) or cellular phosphoglycerate kinase (PGK) pro-
moters. LIS1 induces transcription from CMV promoter
(Fig. 4A) but inhibited transcription from PGK promoter
(Fig 4B). In contrast, expression of Bγ inhibited both CMV
and PGK-mediated transcription (Fig. 4).
The WD5 domain of LIS1 inhibits phosphorylase-
phosphatase activity of PP2A
To determine whether the effect of LIS1 is due to the inhi-
bition PP2A, we analyzed the effect of LIS1 on the phos-
phorylase phosphatase activity of PP2A. Glycogen
phosphorylase-a, a general substrate of PP2A and PP1
phosphatases was prepared by phosphorylating phospho-
rylase-b with phosphorylase kinase using (γ32P) ATP [26].
The (32P)-labeled phosphorylase-a was then used as a sub-
strate for PP2A. We also used PP1 as a control. LIS1 inhib-
ited the phosphorylase phosphatase activity of PP2A in a
concentration-dependent manner (Fig. 5). In contrast,
LIS1 had no effect on the phosphorylase phosphatase
activity of PP1 (Fig. 5). When purified peptides containingRetrovirology 2006, 3:65 http://www.retrovirology.com/content/3/1/65
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LIS1 induces HIV-1 transcription Figure 1
LIS1 induces HIV-1 transcription. A and B, 293 cells grown in DMEM to 50% confluency were transfected with a LIS1 
expression vector (panel A, lane 1), Flag-Bγ expression vector (panel B, lane 2) or pCI expression vector. Cells were lysed in 
SDS-loading buffer. Lysates were resolved on 12% SDS PAGE followed by immunoblotting with anti-LIS1, anti-α-tubulin or 
anti-Flag antibodies as indicated. C, 293 cells were grown to 50% confluency and transfected with different concentrations of 
vectors expressing LIS1 (lanes 3–5) or Bγ subunit of PP2A (lanes 6–8) combined with HIV-1 LTR lacZ and Tat expression vec-
tors. The pCI-neo vector was added to keep constant the amount of CMV promoter-containing pCI vector in the transfection. 
Lane 1, control transfected with only HIV-1 LTR-LacZ. Lane 2, control transfected with HIV-1 LTR-LacZ and Tat expression 
vectors. Expression of β-galactosidase was analyzed using ONPG-based assay. The results are expressed as a fold of transacti-
vation.
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Upregulation of HIV-1 transcription by okadaic acid Figure 2
Upregulation of HIV-1 transcription by okadaic acid. 293 cells were grown to 50% confluency and transfected with a 
combination of HIV-1 LTR-LacZ and Tat expression vectors (panel A) or TAR deleted mutant of HIV-1 LTR-LacZ expression 
vector (panel B). Okadaic acid was added in increasing concentrations and the cells were assayed for β-galactosidase at 48 
hours posttransfection. The results are expressed as a fold of transactivation.
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WD5 domain of LIS1 upregulates Tat mediated HIV-1 transcription Figure 3
WD5 domain of LIS1 upregulates Tat mediated HIV-1 transcription. A. The WD5 domain and N-terminal domain of 
LIS1 were expressed in E. coli and extracted from the inclusion bodies as described in Methods. The dialyzed peptides were 
resolved on 12% SDS-PAGE gel and stained by Coumassie blue. B. 293 cells transfected with HIV-1 LTR-LacZ and Tat expres-
sion vectors and treated at 24 hrs posttransfection with WD5 domain or the N-terminal domain of LIS1. C, 293 cells trans-
fected with TAR RNA-deleted HIV-1 LTR-LacZ vector and treated as in panel A. The results are presented as a fold of 
transactivation.
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293T cells were grown to 50% confluency and transfected with vectors expressing EGFP under the control of CMV (panel A)  or PGK (panel B) promoters without or with vectors expressing LIS1 or Bγ subunit of PP2A Figure 4
293T cells were grown to 50% confluency and transfected with vectors expressing EGFP under the control of CMV (panel A) 
or PGK (panel B) promoters without or with vectors expressing LIS1 or Bγ subunit of PP2A. The EGFP expression was meas-
ured by fluorescence in the cellular lysates at 480 nm excitation and 510 nm emission as described in Methods.
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WD5 or N-terminal domains of LIS1 were used instead of
full length LIS1, we observed inhibition of PP2A activity
by the WD5 but not the N-terminal domain of LIS1 (Fig.
6A). When the peptides were assayed with PP1, no signif-
icant inhibition was observed and the effect of the pep-
tides did not differ at high concentration of the peptides
(Fig. 6B). Our results thus indicate that LIS1 might directly
inhibit PP2A and that the inhibition of PP2A is likely to
be mediated by WD domain(s) of LIS1.
Binding of Tat to LIS1 does not affect the inhibition of 
PP2A by LIS1
We next analyzed whether Tat has an effect on the inhibi-
tion of PP2A by LIS1. Purified recombinant Tat was added
to PP2A or PP1 alone or in combination with LIS1 and
phosphorylase phosphatase activity of PP2A or PP1 was
assayed. Recombinant Tat was expressed in bacteria and
purified by reverse phase chromatography as we previ-
ously described [27]. Tat inhibited PP1 but not PP2A (Fig.
7, lane 1). LIS1 inhibited the activity of PP2A but not PP1
(Fig. 7, lanes 2 and 3). Addition of Tat to LIS1 did not
change the LIS1 inhibition of PP2A (Fig. 7, lanes 4 to 7).
Also addition of LIS1 to Tat did not change the inhibition
of PP1 by Tat (Fig. 7, lanes 4 to 7). Thus Tat has no effect
on LIS1-mediated inhibition of PP2A.
Taken together, our results show that LIS1 upregulates
HIV-1 Tat mediated transcription and that this upregula-
tion could be due to the inhibition or modulation of
PP2A activity by LIS1.
Discussion
Our results presented here show that LIS1 upregulates
HIV-1 transcription possibly by inhibiting PP2A. We dem-
LIS1 inhibits PP2A activity in vitro Figure 5
LIS1 inhibits PP2A activity in vitro. Phosphatase assay was performed as described in Methods. Phosphorylase-a substrate, 
PP1 or PP2A were incubated with indicated concentrations of LIS1 protein. Results are presented as a percent of untreated 
control
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onstrate that the WD domains but not the N terminal
domain of LIS1 are involved in both upregulation of tran-
scription and PP2A inhibition.
LIS1, a microtubule binding protein [28] regulates micro-
tubule dynamics by interacting with dynein motor, NudC
and Dynactin [29,30] and also with Nudel [31]. A yeast
WD5 of LIS1 inhibits PP2A activity invitro Figure 6
WD5 of LIS1 inhibits PP2A activity invitro. Phosphatase assay was performed as described in Methods. Phosphorylase-a 
substrate, PP2A (panel A) or PP1 (panel B) were incubated with indicated concentrations of WD5 or N-terminal peptides. 
Results are presented as a percent of untreated control
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homologue of LIS1, NudF associates with NudC to regu-
late dynein and microtubule dynamics [32,33]. Lissen-
cephaly is a neuronal disease caused by a severe mutation
in the LIS1 gene. Interestingly, HIV-1-associated dementia
is prevalent in the patients with AIDS. Whether there is a
connection between deregulation of LIS1 function and
development of dementia is not yet known, but obviously
this is an intriguing possibility.
We envision a possible mechanism of Tat, LIS1 and PP2A
interaction (Fig 8). We propose that LIS1 binds PP2A core
enzyme and substitutes the B subunit of PP2A holoen-
zyme. By substituting the targeting B subunit of PP2A,
LIS1 may relocate PP2A to a new substrate and also move
it away from its physiological substrate (Fig 8). Tat-
dependent HIV-1 transcription requires the activity of
CDK9, and CDK9 autophosphorylation was shown to be
important for the binding of CDK9/cyclin T1 to TAR RNA
[34]. As we have recently shown PP2A dephosphorylates
CDK9 and pretreatment of CDK9 with PP2A increases
CDK9 autophosphorylation [35]. Thus it is possible that
Tat might coordinate CDK9 dephosphorylation by PP2A
prior to its recruitment to TAR RNA. Activation of CMV
promoter by LIS1 supports this explanation as CMV pro-
moter strongly relies on CDK9 activity [36]. The inhibi-
tory effect of LIS1 on PGK promoter indicates that LIS1
might have a differential effect on cellular promoters. Fur-
ther studies are needed to analyze the effect of LIS1 on cel-
lular gene expression. We previously showed that Tat
interacts with LIS1 in vitro and in vivo and that LIS1 was
part of a larger complex that in addition contained CDK7,
cyclin H, MAT1 [10]. It is possible that interaction of Tat
LIS1 inhibition of PP2A is not altered by Tat Figure 7
LIS1 inhibition of PP2A is not altered by Tat. Phosphatase assay was performed as described in Methods. PP2A (open 
bars) or PP1 (closed bars) were assayed in the presence of LIS1 and/or Tat. Lane 1, 1 μg of Tat. Lane 2, 0.2 μg of LIS1. Lane 3, 
0.4 μg of LIS1. Lane 4, 0.5 μg of Tat and 0.2 μg of LIS1. Lane 5, 0.5 μg of Tat and 0.4 μg of LIS1. Lane 6, 1 μg of Tat and 0.2 μg 
of LIS1. Lane 7, 1 μg of Tat and 0.4 μg of LIS1.
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Proposed mechanism of Tat, LIS1 and PP2Ainteraction Figure 8
Proposed mechanism of Tat, LIS1 and PP2Ainteraction. Binding of Tat to LIS1 may rearrange LIS1 binding to microtu-
bules to allow its interaction with PP2A core enzyme.
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with this complex might activate CDK7 and ultimately
affect viral gene expression through a direct activation of
CDK7 or indirectly through activation of a down stream
kinase, CDK2, which we recently showed to be important
for HIV-1 transcription [37,38]. As Tat is shuttling
between nucleus and cytoplasm, its interaction with LIS1
and CDK7-containing protein complex might allow a
temporary activation of the CDK7 activity. Although LIS1
is a cytoplasmic protein, it is often found in the perinu-
clear area where the initial assembly of the complex con-
taining CDK7 might take place. Finally, LIS1 may also
remove PP2A away from IκB, promoting IκB phosphor-
ylation by IκK and release and activation of NF-κB. The
liberated NF-κB translocates to the nucleus and increases
transcription from responsive promoters including HIV-1
LTR. Taken together, there are number of potential path-
ways that can be affected by LIS1 interaction with PP2A.
Further studies are needed to clarify the detailed mecha-
nism of LIS1 induction of HIV-1 transcription and the role
of LIS1 in HIV-1 pathogenesis.
Methods
Materials
PP1 was a generous gift from Dr. Bollen (Catholic Univer-
sity of Leuven, Belgium). PP2A was purchased from
Upstate (Chicago, IL). Rabbit polyclonal LIS1 antibodies
were purchased from Novus Biologicals. Anti-Flag and
anti-a-tubulin antibodies were from Sigma.
Plasmids
The HIV-1 reporter contained HIV-1 LTR (-138 to +82)
followed by a nuclear localization signal (NLS) and the
LacZ reporter gene (courtesy of Dr. Michael Emmerman,
Fred Hutchinson Cancer Institute, Seattle, WA). It
expresses NLS-tagged β-galactosidase under the control of
HIV-1 LTR (16). The HIV-1 reporter plasmid without TAR
contained a deletion of +19 to +87 nucleotides of LTR
introduced by restriction digestion with BglII. The Tat
expression plasmid was a gift from Dr. Ben Berkhout
(University of Amsterdam) (17). The CMV-EGFP cloned
into the Adenovirus shuttle vector was a gift from Dr.
Marina Jerebtsova (Children's National Medical Center).
The SIN vector containing phosphoglycerol kinase (PGK)
promoter followed by EGFP [39] was a gift from Dr. John
Tisdale (NIDDK, NIH). The PP2A Bγ expression vector
[24] was a gift from Dr. Stefan Strack (University of Iowa).
Expression and purification of WD5 and N terminal of LIS1
The DNA sequences encoding each of the seven WD
domains and the amino terminal domain of LIS1 were
subcloned into a plasmid carrying T7 promoter upstream
of the multiple cloning site and a myc tag and ampr mark-
ers. These vectors were created at the laboratory of Dr.
Orly Reiner (The Weizmann Institute of Science, Israel)
and were kindly given to us. The DNA was transformed
into E. coli BL21 SI cells. The cells were grown to mid log
phase, and synthesis of recombinant proteins was
induced by the addition of NaCl to a final concentration
of 0.3M for 18 hours according to the recommendation of
manufacturer (Invitrogen). The cells were lysed by sonica-
tion in a buffer A (10 mM Tris-HCl (pH 7.8), 50 mM
NaCl, 1 mM EDTA 1 mM PMSF, 20% glycerol) and inclu-
sion bodies were recovered by centrifugation. Inclusion
bodies were dissolved in the buffer A containing addition-
ally 6M urea and proteins were concentrated on micro-
cone spinning tubes (Millipore, Billerica, MA). The
recombinant proteins were dialyzed against PBS before
usage.
Cell culture and transfection
Cells were maintained in Dubelco Modified Eagles
Medium (DMEM) supplemented with 10% FBS and
0.1%penicillin/streptomycin. HEK293 cells were subcul-
tured 24 hrs prior to transfection to achieve 60% conflu-
ence on the day of transfection. Transfections were carried
out in 96 well plates and in some experiments in 6 well
plates. Transfections were performed by calcium phos-
phate precipitation as previously described [40].
Subcloning of pCI-LIS
LIS1 gene was subcloned from pAGA2 vector [10] to pCI-
Neo eukaryotic expression vector (Promega, Madison,
WI). The pAGA2-LIS1 plasmid was digested with EcoR1
and Sal1 to extract LIS1 fragment. The LIS1-containig
DNA fragment was purified on the agarose gel and ligated
into the pCI-Neo digested with EcoR1 and Sal1. The
resulting plasmid pCI-LIS was checked by restriction
digestion with EcoR1 and Sal1 to visualize ligation prod-
ucts on an agarose gel and also by sequencing with T7 and
T3 primers.
β-galactosidase assay
HEK 293 cells transfected with HIV-1 LTR-LacZ and HIV-
1 Tat expression vectors were lyzed and the level of tran-
scription from the HIV-1 LTR was determined by measur-
ing the β-galactosidase activity as previously described
[40]. Briefly, cells were washed with phosphate-buffered
saline (PBS) and lysed for 20 min at room temperature in
50 μl of lysis buffer, containing 20 mM HEPES at pH 7.9,
0.1% Nonidet P-40, and 5 mM EDTA. Subsequently, 100
μl of o-nitrophenyl-β-D-galactopyranoside (ONPG) solu-
tion (72 mM Na2PO4 at pH 7.5, 1 mg/ml ONPG, 12 mM
MgCl2, 180 mM 2-mercaptoethanol) was added and incu-
bated at room temperature until a yellow color developed.
The reaction was stopped by addition of 100 μl of 1 M
Na2CO3. The 96-well plates were analyzed in a micro
plate reader at 414 nm (Lab Systems Multiscan MS). The
β-galactotosidase units were calculated using a linear
graph plotted from optical density (OD) readings of the
standard.Retrovirology 2006, 3:65 http://www.retrovirology.com/content/3/1/65
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Florescence measurement
293T cells transfected in 96-well plate were lysed in 50 μl
of lysis buffer per well (20 mM HEPES at pH 7.9, 0.1%
Nonidet P-40, and 5 mM EDTA), then supplemented with
150 μl of PBS and transferred to fluorescent-compatible
96-well plate. The GFP fluorescence was measured at 480
nm excitation and 510 nm emission on Luminescence
Spectrometer LS50B (Perkin-Elmer) equipped with the
robotic 96-well scanner.
Western blot
Cells transfected with various vectors were washed 3 times
with PBS and then lyzed with lysis buffer containing 50
mM Tris-HCl (pH 7.5), 0.5 M NaCl, 1% NP-40, 0.1% SDS
and protease inhibitor cocktail (Sigma). The control cell
extracts were prepared from mock-transfected 293T cells.
About 5 μg whole cell extract proteins were resuspended
in a 30 μl of 1× SDS loading buffer (4% SDS, 10% glyc-
erol, 5% 2-mecarpthaethanol, 0.002% bromophenol
blue) and heated at 90°C for 3 minutes. The proteins were
resolved on 10% SDS Polyacrylamide gel electrophoresis
(PAGE) and immunoblotted with anti-LIS1 or anti tubu-
lin antibodies
Phosphatase assay
Phosphorylase-a  was prepared as previously described
[26]. Approximately 0.2 nmol of phosphorylase-a  was
used as a substrate for PP1 or PP2A. The phosphorylase
phosphatase assay was carried out for 10 min in a buffer
containing 50 mM glycylglycine at pH 7.4, 0.5 mM dithi-
othreitol, and 5 mM β-mercaptoethanol as described [41].
Where indicated, prior to the phosphorylase phosphatase
assay, the samples were trypsinized to generate free, active
catalytic subunit of PP1.
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